Vistagen appoints Paul Edick to Board of Directors, effective October 27, 2025

Vistagen Therapeutics, Inc.

Mr. Edick appointed to Board, Audit Committee, and Compensation Committee.
Received options to purchase 35,200 shares at $3.90/share (closing price on appointment date), vesting over 3 years.
He is entitled to annual cash and equity compensation under the Director Compensation Plan.
Mr. Edick is former Chairman/CEO of Xeris Pharmaceuticals and ex-CEO of Durata Therapeutics.
No family relationships or transactions with the company requiring disclosure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.